4D Molecular Therapeutics vs Protalix BioTherapeutics
FDMT and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FDMT and PLX compare
4D Molecular Therapeutics is the larger company, worth 3.7 times as much as Protalix BioTherapeutics ($938M against $252M).
4D Molecular Therapeutics grew revenue faster over the last twelve months (278712% versus 37.0% for Protalix BioTherapeutics).
Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 24.3% compared with −195% at 4D Molecular Therapeutics.
Protalix BioTherapeutics scores higher on the StockData Score (16 against 7 for 4D Molecular Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FDMT | PLX |
|---|---|---|
| Size and price | ||
| Market cap | $938M | $252M |
| Share price | $12.99 | $3.13 |
| Change, 1 year | 27.7% | 46.9% |
| Change, 5 years | −43.7% | 219% |
| Beta (5Y) | 1.35 | 0.87 |
| Employees | 196 | 226 |
| StockData Score | ||
| Total score | 7 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 2 | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 12.5× |
| P/S | 10.2× | 3.0× (better) |
| P/B | 2.3× (better) | 3.1× |
| EV/EBITDA | – | 9.1× |
| P/FCF | – | 16.7× |
| FCF yield | – | 6.0% |
| Fair value | $12.76 | $6.08 |
| Margin of safety | −1.8% | 48.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 278712% (better) | 37.0% |
| Revenue growth, 5Y average | 44.3% (better) | −3.5% |
| Net income growth (TTM) | – | 281% |
| EPS growth (TTM) | – | 525% |
| Profitability | ||
| Gross margin | – | 71.2% |
| Operating margin | −214% | 29.8% (better) |
| Net margin | −195% | 24.3% (better) |
| FCF margin | – | 17.8% |
| Return on equity | −43.3% | 30.8% (better) |
| Return on invested capital | −161% | 41.0% (better) |
| Financial health | ||
| Debt / equity | 0.05 (better) | 0.00 |
| Current ratio | 8.03 (better) | 3.27 |
| Altman Z-score | 3.87 | 6.13 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 80.5% | 17.9% |
| Held by insiders | 2.1% | 3.8% |
| Insider net buying, 12 months | −$5.3M | $101K (better) |
| Short interest, % of float | 15.4% | 4.5% |
Go deeper
- FDMT stock overview
- FDMT income statement
- FDMT valuation and score
- PLX stock overview
- PLX income statement
- PLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.